Global Cell and Gene Therapy Market - 2024-2031

Overview

Global Cell and Gene Therapy Market reached US$ 16.5 billion in 2023 and is expected to reach US$ 70.1 billion by 2031, growing at a CAGR of 18.6% during the forecast period 2024-2031.

Cell therapy involves transferring live cells to a patient to treat or prevent diseases. These cells can be autologous or allogeneic, and can transform into different cell types. Pluripotent cells can transform into any cell type, while multipotent cells have a more limited repertoire. Differentiated or primary cells are fixed types, and the type of cells administered depends on the treatment.

Gene therapy is the use of genetic material to treat or prevent diseases by altering the production of a single or group of proteins in cells. It can reduce disease-causing protein levels, increase disease-fighting protein production, or produce new or modified proteins.

Market Dynamics: Drivers & Restraints

Increasing collaboration between the key market players to develop new gene therapies

The cell and gene therapy market is growing due to strategic alliances among biotechnology firms, pharmaceutical companies, and academic institutions. These partnerships enable sharing of expertise, technology, and resources, facilitating faster clinical trials and regulatory approvals. They also help companies address complex genetic disorders more effectively and expand their pipelines.

For instance, on February 15, 2023, Charles River Laboratories International, Inc., a pharmaceutical company, and Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration. Under the collaboration, the gene therapy platform targeting renal diseases, using Charles River's established plasmid platform, eXpDNA, and decades of experience at the company's plasmid DNA manufacturing center of excellence.

Challenges associated with the cell and gene therapy

The development of CAR T-cell therapies faces challenges such as safety and efficacy issues, clinical study protocols, strict regulatory frameworks, and high costs. Key elements include treating heterogeneous systems with various cells, high gene transfer efficiency, low cell toxicity, and single cell specificity.

However, one in five cancer patients who qualify for these therapies die waiting for production facilities. Despite these challenges, some autologous products can now be produced in less than two weeks. The health sector is exploring the development of more sophisticated gene-transfer tools with CARs and centralized organization with standardized apheresis centers, such as collection and reinfusion.

Segment Analysis

The global cell and gene therapy market is segmented based on therapy type, therapeutic area, mode of delivery, end user and region.

The cell therapy from the therapy type segment accounted for approximately 54.3% of the cell and gene therapy market share

The cell therapy from the therapy type segment accounted for approximately 54.3%. implants are vital for osseointegration, a process where the implant acts as an artificial tooth root. Cell therapy is a key player in the cell and gene therapy market, offering transformative treatments for diseases like cancer, autoimmune disorders, and genetic conditions.

Cell-based therapies like CAR-T cells and stem cell therapies repair, replace, or regenerate damaged tissues and organs. The success of CAR-T cell therapies in treating cancer has increased interest and investment in the field. As clinical trials show positive outcomes, cell therapy is seen as a vital component of precision medicine, driving personalized healthcare advancements and expanding market applications.

For instance, in August 2024, the Food and Drug Administration (FDA) approved a cellular therapy called afamitresgene autoleucel, or afami-cel (Tecelra), to treat some people with metastatic synovial sarcoma, a type of soft tissue sarcoma. The decision marks the first time the agency has approved a treatment called a T-cell receptor (TCR) therapy for cancer.

Geographical Analysis

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period due to rise in the prevalence of cancers, FDA approvals, highest number of gene therapy clinical trials, with over 400 enterprises actively developing cell and gene therapy products for various disorders.

For instance, in April 2024, Walgreens proposed to collaborate with drugmakers to offer cell and gene therapies to US patients as part of its expansion of specialty pharmacy services. The company will open a licensed facility in Pittsburgh for these services, as specialty pharmacies play a crucial role in the US health system, particularly in the fight against chronic diseases.

Market Segmentation

By Therapy Type

• Cell Therapy
• Gene Therapy

By Therapeutic Area

• Oncology (Cancer)
• Rare Diseases
• Cardiovascular Diseases
• Neurological Disorders
• Ophthalmology
• Orthopedic Diseases
• Hematological Disorders
• Others

By Mode of Delivery

• In Vivo
• Ex Vivo

By End-User

• Hospitals & Clinics
• Research Institutes
• Biopharmaceutical Companies
• Academic Institutions

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include Novartis, Gilead Sciences (Kite Pharma), Bristol-Myers Squibb, Bluebird Bio, Spark Therapeutics (Roche), Sarepta Therapeutics, UniQure, Biomarin Pharmaceutical, Fate Therapeutics, Cellectis among others.

Key Developments

• In April 2024, India has launched its first indigenous CAR T-cell therapy, NexCAR19, for cancer treatment. The therapy, developed by IIT Bombay and the Tata Memorial Centre, is a "major breakthrough" that offers a new hope for the fight against the disease. The therapy, which is the first "Made in India" CAR T-cell therapy, will help cure various types of cancer and significantly reduce the cost of cancer treatment. The launch event took place at the Indian Institute of Technology (IIT) Bombay in Mumbai.
• In August 2024, Precigen, Inc., a biopharmaceutical company, has announced a strategic reprioritization of its clinical portfolio and resource streamlining, including a 20% workforce reduction, to focus on commercializing the PRGN-2012 AdenoVerse gene therapy for recurrent respiratory papillomatosis, a treatment that could improve patient lives.

Why Purchase the Report?

• To visualize the global cell and gene therapy market segmentation based on therapy type, therapeutic area, mode of delivery, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of the cell and gene therapy market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global cell and gene therapy market report would provide approximately 64 tables, 61 figures and 186 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies